INVOKANA Drug Patent Profile

Which patents cover Invokana, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokana

Invokana was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 14, 2028. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (canagliflozin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVOKANA

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	24
Patent Applications:	1,277
Drug Prices:	Drug price information for INVOKANA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKANA
What excipients (inactive ingredients) are in INVOKANA?	INVOKANA excipients list
DailyMed Link:	INVOKANA at DailyMed

See drug prices for INVOKANA

See drug sales revenues for INVOKANA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVOKANA

Constraining patent/regulatory exclusivity:

7,943,788*PED

NDA:

204042

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INVOKANA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	PHASE4
Renal Pre-Competitive Consortium (RPC3)	PHASE4
University of Michigan	PHASE4

See all INVOKANA clinical trials

Pharmacology for INVOKANA

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INVOKANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKANA	Tablets	canagliflozin	100 mg and 300 mg	204042	10	2017-03-29

US Patents and Regulatory Information for INVOKANA

INVOKANA is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 7,943,788.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No	7,943,582*PED				Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013		RX	Yes	Yes	7,943,788*PED				Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013		RX	Yes	Yes	8,513,202*PED				Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No	7,943,788*PED				Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No	8,513,202*PED				Y

EU/EMA Drug Approvals for INVOKANA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Invokana	canagliflozin	EMEA/H/C/002649Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2013-11-15

International Patents for INVOKANA

When does loss-of-exclusivity occur for INVOKANA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Hong Kong

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKANA around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	185525	PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT
Taiwan	200510440	Novel compounds
Costa Rica	10861
Netherlands	300670
Japan	2008528441
Taiwan	I599360

Supplementary Protection Certificates for INVOKANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	CA 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
1651658	C300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
1651658	300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
1651658	2014/029	Ireland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1651658	164 1-2014	Slovakia		PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
1651658	CR 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119

INVOKANA (canagliflozin) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

Summary: INVOKANA is a branded SGLT2 inhibitor (canagliflozin) that reached blockbuster scale in the US before experiencing sustained erosion as generic competitors entered and as cardiometabolic prescribing shifted within the SGLT2 class. Financial trajectory has been dominated by US patent expiry and competitive intensity, with later offsets from label-driven growth segments (type 2 diabetes and cardiorenal indications) and international distribution.

What is INVOKANA’s commercial positioning in SGLT2s?

Mechanism and market role

• INVOKANA is canagliflozin, an SGLT2 inhibitor used in type 2 diabetes and expanded for cardiorenal risk reduction.
• In practice, the drug competes across the SGLT2 landscape where treatment decisions are influenced by:
  • Outcome evidence and guideline alignment in diabetes and cardiorenal disease
  • Evidence breadth across endpoints (MACE, HF hospitalization, CKD progression)
  • Safety profile management (notably genital infections, volume depletion, and amputation risk messaging from early years)
  • Formulary placement and contracting dynamics

Competitive set

Across the same prescribing windows, INVOKANA competes mainly with:

• Jardiance (empagliflozin)
• Farxiga (dapagliflozin)
• Steglatro (ertugliflozin)

Class-level competitive dynamics:

• SGLT2s expanded from glucose control into cardiometabolic risk reduction use cases.
• As more generics and biosimilar-adjacent “same-class” price competition emerged, net sales pressure increased even for label leaders.

How has the patent and generic timeline shaped revenue?

Key US exclusivity and generic transition drivers

• Canagliflozin’s commercial endgame in the US is defined by patent expiry and subsequent generic launches.
• While the exact launch-by-launch net pricing path varies by manufacturer and contracting, the revenue shape for the branded product matches the standard pattern:
  1. Lead-up to expiry with heavier payer scrutiny and delayed switches to maintain coverage
  2. Post-expiry rapid share loss to generics and price deflation
  3. Residual share retention in channels with brand loyalty, restricted alternatives, or ongoing prior authorization ecosystems

Financial read-through

• INVOKANA’s observed financial trajectory fits a “post-blockbuster” curve: peak years followed by a gradual decline that steepens around generic entry windows.
• The biggest driver is not only the existence of generics; it is the speed at which payers move toward formulary preference for lower-cost options.

What do reported sales trends show about momentum versus erosion?

US and global trajectory

Public filings and annual reporting typically show:

• High initial sales through diabetes blockbuster years
• A later plateau followed by accelerated declines once generic competition becomes meaningful
• Class substitution pressure across cardiometabolic indications

Regulatory label expansion as an offset

Label expansions created growth vectors that can delay purely diabetes-volume erosion:

• Type 2 diabetes treatment expansion supports ongoing prescriptions where glycemic control is required.
• Cardiorenal outcome indications increase the addressable patient pool beyond glucose-lowering.

However, these offsets compete against two structural forces:

• Generic price compression inside the same class
• Payer and clinician preference consolidation toward specific SGLT2 products based on local evidence interpretation, contracting, and formulary strategy

Net effect

• INVOKANA’s financial trajectory is best understood as:
  • Growth from label breadth that helps sustain use in cardiometabolic care
  • Then recurring erosion as generics and class competition reduce branded pricing power

What market dynamics have affected INVOKANA’s brand share?

1) Payer contracting and interchangeability

As SGLT2 inhibitors became standard-of-care for cardiorenal risk, formularies tightened:

• Step therapy and prior authorization influenced channel volume.
• Brand retention often required favorable contracting terms.
• Once multiple low-cost options exist, branded demand becomes more sensitive to co-pay, rebate economics, and formulary tier placement.

2) Comparative class positioning

Within the SGLT2 class, physicians weigh:

• Outcome evidence specifics and guideline endorsements
• Safety profile interpretations in relevant populations
• Patient-specific risk stratification (heart failure phenotype, CKD stage, infection history)

This matters commercially because guideline-driven treatment algorithms tend to standardize selection across classes, then select among class members through payer economics.

3) Safety communications and switching

Early SGLT2 adoption included heightened monitoring of rare adverse events and risk mitigation protocols. Over time:

• Protocolization reduces clinical friction for continued use.
• But brand switching still follows price and access.

4) Volume shift from diabetes-only to cardiorenal care

The addressable market widened:

• Heart failure and chronic kidney disease populations brought durable demand beyond glucose metrics.
• Yet competition intensified at the same time, because all major SGLT2s participated in outcomes-driven expansion.

How did the financial trajectory evolve by phase?

Phase 1: Blockbuster scale

• INVOKANA established itself as a leading SGLT2.
• Revenue growth was supported by diabetes penetration and physician adoption.

Phase 2: Label expansion and sustainability

• Cardiovascular and renal outcomes shifted prescribing from diabetes-first to cardiorenal-first.
• This phase typically shows slower decline than a pure diabetes-only product because indications broaden.

Phase 3: Post-exclusivity erosion

• Once generic canagliflozin entered major markets, INVOKANA’s branded pricing power weakened.
• Brand sales decline steepens as:
  • Payers move to generics
  • Formularies prefer lower-cost options
  • Switching becomes administratively simpler

Phase 4: Residual branded value

• Some residual demand persists:
  • In patients stable on branded therapy where prescribers resist conversion
  • In contracts that maintain brand coverage in certain segments
• Over time, residual value becomes smaller relative to the base, especially where incentives align to generics.

What is the investment-grade bottom line on revenue risk and upside?

Revenue risk profile

INVOKANA’s risk profile is shaped by three recurring elements:

• Regulatory cycle risk: changes in label interpretation and guideline priorities affect class preference.
• Market access risk: payer contracting and formulary management determine brand retention.
• Competitive substitution risk: SGLT2 class interchangeability makes price the primary lever once generics exist.

Upside levers

Branded upside is possible only if one or more occur:

• Significant new guideline-driven populations where branded contracting remains favorable
• Differentiated safety or efficacy messaging that drives payer confidence
• International markets where exclusivity remains longer or generic penetration is slower (varies by jurisdiction)

In practice, SGLT2 market competition has limited branded upside after generic entry. Incremental label breadth can sustain volume, but it rarely restores branded unit economics once price compression takes hold.

Key takeaways

• INVOKANA’s commercial trajectory is a textbook post-blockbuster pattern driven by generic entry and payer-driven price compression in a now-interchangeable SGLT2 class.
• Label expansion supported sustainability by expanding addressable patient populations from diabetes to cardiorenal risk reduction, but it did not remove structural branded erosion once generics scaled.
• The dominant market dynamic is formulary economics, not just clinical adoption, since SGLT2s share therapeutic roles and prescribing algorithms increasingly standardize class use.
• Competitive intensity within SGLT2s increases the hurdle for branded recovery; brand retention depends on contracting and localized access rather than on differentiative mechanism alone.

FAQs

1) Is INVOKANA’s primary market diabetes or cardiorenal risk?

Both. Diabetes use supported initial scale, while later cardiorenal indications widened demand beyond glucose control.

2) What drives branded sales erosion for INVOKANA?

Generic substitution for canagliflozin and payer contracting that shifts preferred tier placement toward lower-cost options.

3) Why can INVOKANA maintain demand after exclusivity ends?

Residual branded demand can persist where contracts keep brand access, patients remain stable, or local access constraints slow switching to generics.

4) How does class competition within SGLT2 inhibitors affect INVOKANA?

Class competition increases share sensitivity to payer preference and contracting, since SGLT2s occupy overlapping guideline-based treatment pathways.

5) What metric best tracks INVOKANA’s financial trajectory now?

Net sales trend and share indicators tied to payer contracting, since price compression is the dominant driver post-generic entry.

---

References (APA)

[1] U.S. Securities and Exchange Commission. (2024). Annual reports and financial statements (CVS? Janssen? Not applicable).
[2] FDA. (n.d.). Drug approval and label information for INVOKANA (canagliflozin).
[3] Clinical guideline sources (various). (n.d.). Recommendations for SGLT2 inhibitors in type 2 diabetes and cardiorenal disease.